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Background: Behcet's disease (BD) is a systemic inflammatory disease with the histopathological features of
leukocytoclastic vasculitis that affects nearly all organs and systems. When it involves the intestine, it is called
entero-Behcet's disease (entero-BD).
Case presentation: Here we described a 23-year-old man with entero-BD refractory to conventional therapies who
responded well to the combination therapy of infliximab, an anti-tumor-necrosis-factor (TNF)-alpha antibody, and
thalidomide. After combination treatment, the patient’s symptoms improved greatly and his Crohn's Disease Activity
Index (CDAI) score decreased from 344 to 52 points, accompanied by a body weight increase from 53 kg to 64 kg.
A follow-up endoscopy performed 10 weeks after the treatment showed significant improvement and the patient's
multiple ulcers had healed well.
Conclusion: The combination therapy of infliximab and thalidomide appears to be clinically effective in a patient
with refractory entero-BD. However, further studies need to be performed to evaluate the efficacy of this combination
therapy.
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Behcet's disease (BD) is a chronic relapsing vasculitis
characterized by recurrent oral and genital ulcerations
with uveitis and is more prevalent around countries
along the ancient Silk Route [1]. Entero-Behcet's disease
(entero-BD) is characterized by intestinal inflammation
with round and oval ulcers typically in the ileocaecum
and is associated with gastrointestinal symptoms, which
are often uncontrollable, relapsing, and can cause acute
intestinal bleeding or perforation [2,3]. Gastrointestinal
involvement has been reported in 3%–26% of patients
with BD [4]. The etiology of BD is still unknown, but
tissue damage that occurs in BD patients is believed to
be caused by oxygen radicals, which are generated by pro-
inflammatory cytokines and arachidonic acid metabolites* Correspondence: liuside@163.com
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reproduction in any medium, provided the or[5,6]. Although corticosteroids, 5-aminosalicylic acid
derivatives, immunosuppressive agents, and immuno-
modulators have been used to treat BD patients with
varying degrees of success, BD is associated with severe
morbidity and considerable mortality [7]. Tumor necrosis
factor (TNF)-alpha plays an important role in this T
helper cell type 1 (Th1)-mediated disease [8]. Inflixi-
mab, a monoclonal antibody to TNF-alpha, which neu-
tralizes TNF-alpha and down-regulates the expression
of granulocyte-macrophage colony-stimulating factor has
been demonstrated to be an effective therapy for Crohn's
disease, rheumatoid arthritis and other Th1-mediated
disorders [9]. However, the single use of infliximab is
not efficient in all BD patients [10,11]. Thalidomide select-
ively inhibits the production of TNF-alpha in monocytes
and reduces its activity by a mechanism distinct from
infliximab [12,13]. Many publications have reported the
possible use of thalidomide for a wide range of conditions
such as BD [14-17]. Here, we utilized a combination
therapy of infliximab and thalidomide and showed thathis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Li et al. BMC Gastroenterology 2013, 13:167 Page 2 of 6
http://www.biomedcentral.com/1471-230X/13/167it appears to be clinically effective in a patient with
refractory entero-BD.
Case presentation
A 23-year-old man was admitted to our hospital because
he had recurrent abdominal pain and fever for more than
2 years. The patient began to have a burning pain in the
epigastrium in October 2008, which mostly occurred at
night and when he was hungry. The pain occurred once
every 1 to 2 months, each time lasting for 1 to 2 days, ac-
companied by fever, with temperature fluctuating between
38-39°C, which would alleviate by itself. The patient
did not have diarrhea, night sweats or other symptoms.
Laboratory examination in the local hospital revealed
white blood cell (WBC) 10.0 × 109/L (normal 3.6-9.7 ×
109/L), neutrophil rate 79.2% (normal 50–70%),
hemoglobin 116 g/L (normal 120–160 g/L) and C-
reactive protein (CRP) 87.7 mg/L (normal 0–5 mg/L).
Erythrocyte sedimentation rate (ESR) was 27.0 mm/h
(normal 0–15 mm/h), and occult blood test (OBT) was
positive. The patient was a non-smoker with no family
history of inflammatory bowel disease. Gastroscopy re-
vealed duodenal bulb ulcers. Although acid inhibitors
and antipyretics were used in the local hospital, his
symptoms did not improve. He was referred to our depart-
ment for further evaluation. On admission, a physical
examination found an enlarged submental lymph node
which was soft and removable without pressing pain.
After admission, laboratory examination indicated that
WBC, OB, CRP, and ESR were normal. The patient
tested negative for autoantibodies to nuclear antigen,
double-stranded deoxyribonucleic acid, nuclear ribonu-
cleoprotein, anti-saccharomces cerevisiae antibodies
and anti-neutrophil cytoplasmic antibodies. In addition,
Pathergy and Widal tests were both negative. Gastros-
copy and double balloon enteroscopy revealed duodenal
bulb ulcers and scattered round small ulcers in the je-
junum with no evidence of Helicobacter Pylori infection
(Figure 1A, 1B). Biopsy of a deeply ulcerated area of
jejunum revealed nonspecific mucosal inflammationFigure 1 Related auxiliary examinations were conducted in order to m
on the anterior wall of the duodenum from a healed ulcer (A). Double bal
hyperemia and erosion (B). Biopsy specimens from the jejunum revealed c
lymphocytes and plasma cells (C).without granulomata (Figure 1C). Positron emission
tomography/computed tomography (PET-CT) found
multiple and flake concentration around the jejunum
and ileum. Inflammatory and hyperplastic lymph nodes
without increased metabolism were found in the abdom-
inal, retroperitoneal and mesenteric region (Figure 2).
Although various test had been conducted, the diagnosis
of the patient remained unresolved. His medical history
was long and he did not complaint of hematochezia. PET-
CT scans did not reveal the presence of any abdominal
mass nor any sign of neoplasma. Most significantly, the
biopsy specimen from the deeply ulcerated area of the
jejunum did not show the presence of lymphoma cells,
therefore the possibility of intestinal lymphoma was ex-
cluded. Coeliac disease is more prevalent in Caucasian,
but our patient is an Asian. Meanwhile, eating wheat
foods does not have obvious relation with the patient’s
symptoms. Therefore, the possibility of coeliac disease
was also excluded. However Crohn's disease, tubercu-
losis of the intestines and BD were difficult to differenti-
ate from each other and remained possible causative
conditions. After discharge, the patient still suffered
from recurrent abdominal pain. He returned to our de-
partment with recurrent abdominal pain and fever in
March 2012. On further investigation it was discovered
that the patient had had recurrent oral ulcers, genital
ulcers and occasional blurred vision since childhood.
Capsule endoscopy was carried out and revealed multiple
ulcers in the small intestine, mainly located in the jejunum
(Figure 3A, 3B). BD is diagnosed based on clinical evalu-
ation. Our patient was diagnosed with entero-BD based
on the International Criteria for Behcet’s Disease [18].
However, although he had been treated with prednisone,
mesalazine, cyclophosphamide and colchicines in the local
hospital, his symptoms had not improved. After discussion
with the patient, a combination therapy including inflixi-
mab (5 mg/kg), thalidomide (100 mg,qd) and prednisone
(15 mg/day) was prescribed. Infliximab was infused at
weeks 0, 2, 6, 14, 22 and 30 according to instructions. No
medication-related adverse reactions were observed andake a definitive diagnosis. Gastroscopy revealed a scar (arrow) left
loon enteroscopy revealed a round ulcer (arrow) characterized by
hronic inflammatory infiltrate consisting of a mixture of neutrophils,
Figure 2 PET-CT revealed multiple enlarged lymph nodes (arrow) in the abdominal and mesenteric region without abnormal
concentration of 18 F-fluorodeoxyglucose (18 F-FDG).
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treatment. After the first infusion with infliximab the
patient’s abdominal pain and fever disappeared despite
complete withdrawal of steroids. CRP decreased from
87.7 mg/L to 0.7 mg/L and ESR decreased from
27.0 mm/h to 4 mm/h. Because most of his symptoms
were gastrointestinal, the Crohn's Disease Activity Index
(CDAI) was selected as an objective measure of response
to the therapy. The CDAI score decreased from 344 to 52
points during therapeutic period (Figure 4). Meanwhile,
his body weight increased from 53 kg to 64 kg. Capsule
endoscopy performed 10 weeks after the last infusion
showed marked endoscopic improvement and the
patient's multiple ulcers had healed well (Figure 3C, 3D).
Discussion
Although oral ulceration, genital ulceration and eye dis-
ease are classical triad symptoms of BD, the cardiovascu-
lar, gastrointestinal, musculoskeletal and central nervous
systems can also be affected [19]. The pathogenesis of BD
remains unknown but major determinants involving gen-
etic and immune system abnormalities have been recently
reported [20]. The diagnosis of entero-BD is made accord-
ing to the International Criteria for Behcet’s Disease taking
into account the patient’s gastrointestinal symptoms and
intestinal ulcers as detected by endoscopy. However, whenthe patient’s symptoms are not typical, the diagnosis may
be difficult. In intestinal BD, deep ulcers develop in the
gastrointestinal tract, typically in the ileocaecum. However,
the patient presented in this report had scattered small
ulcers which were mainly in the jejunum. In addition, the
pathergy test was negative, which also complicated the
diagnosis. After collecting a detailed medical history, the
diagnosis was eventually established. In our experience,
comprehensive inquiry and a detailed medical history is
important in the diagnosis of entero-BD as well as
endoscopic examination. When gastroscopic and colono-
scopic investigations do not reveal significant pathological
changes, double-balloon enteroscopy or capsule endos-
copy may contribute to the detection of lesions since
many entero-BD ulcers are atypically located in the ileum
and jejunum. Additionally, the pathergy test is not always
positive and the clinician should not be confused by the
negative results when making a diagnosis of BD.
Entero-BD is often difficult to manage by conventional
therapies such as corticosteroids, 5-aminosalicylic acid
derivatives and immunosuppressive agents. Recently, off-
label use of anti-tumor necrosis factor agents for BD has
increased, suggesting that TNF blockade represents an
important therapeutic approach for patients with severe
and resistant BD, but randomized controlled trials are
lacking [7,21-23]. Infliximab has been reported to have
Figure 3 Before infusion, capsule endoscopy showed multiple oval ulcers with purplish red color change and thin fur attached on the
surface. Congestion and edema of the mucosa can be seen around the ulcers which were widely distributed in the small intestine (A, B).
Repeated capsule endoscopy showed improvement in ulcerations and inflammation 10 weeks after the last infusion (C, D). Most of the ulcers
had healed, leaving a small sheet of erosion (arrow).
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entero-BD [24-27]. Although 91% of BD patients
responded to infliximab, some patients responded
poorly to the treatment of infliximab [10,11,21]. In our
experience, entero-BD patients usually respond poorly
to various conventional treatments such as prednisone,
mesalazine, cyclophosphamide and colchicines, which
were all used for the treatment of our patient in theFigure 4 A CDAI score <150 points is considered clinical remission in
improvement in symptoms, and his CDAI score declined dramatically fromlocal hospital. Since our patient failed to respond to
various conventional treatments, along with the con-
cern that he may respond poorly to a single use of
infliximab, we decided to treat him with a combination
therapy of infliximab and thalidomide, which may
synergize due to a complete blockade of TNF-α.
After the treatment, his symptoms and intestinal lesions
improved without adverse effects. To our knowledge, thisa patient with CD. After the first infusion, the patient noticed great
344 to 100 points, which indicated clinical remission.
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bination therapy of infliximab and thalidomide. The
good response of the patient to this combination ther-
apy is likely a result of a complete TNF-α blockade by
the two agents. Although our report describes only one
case, the improvement in symptoms of the patient sup-
ports evidence that increased levels of TNF-α play a
critical role in the inflammatory process associated
with BD. In view of limitations of the present treatment
for intestinal BD, combination therapy with infliximab
and thalidomide appears to be an effective approach for
the treatment of entero-BD and perhaps other manifes-
tations of BD.
Conclusion
Based on our report, the combination therapy of inflixi-
mab and thalidomide could be selected as an effective
approach for the patients with refractory entero-BD.
However, further studies need to be performed to evalu-
ate the efficacy of this combination therapy.
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